Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction - Trial NCT06264635
Access comprehensive clinical trial information for NCT06264635 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Manitoba and is currently Not yet recruiting. The study focuses on Erectile Dysfunction. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Manitoba
Timeline & Enrollment
Phase 1
Mar 01, 2024
Mar 01, 2025
Primary Outcome
International Index of Erectile Function (IIEF)
Summary
There is great interest in restorative therapies (platelet-rich plasma (PRP) injections,
 shockwave therapy and stem cell therapy) for ED given their non-invasive nature. However,
 data is still limited and requires further research prior to widespread adoption.
 Unfortunately, therapies such as PRP injections are being widely used without clinical
 evidence demonstrating its safety or effectiveness for the treatment of erectile dysfunction.
 2-7 To date, there are no treatments that address the underlying cause of endothelial
 dysfunction, although low-intensity shockwave therapy for ED has shown promising results.
 Platelet-derived therapies targeting inflammation and promoting tissue/nerve regeneration and
 may represent a potential treatment option towards this direction. The investigators propose
 to perform Canada's first pilot RCT to evaluate and safety and efficacy of PRP for the
 treatment of ED.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06264635
Non-Device Trial